20- NCT043
62,189 Efficacy and Safety
Study of Allogeneic
HB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020
DOC: October 2020 Both Child,
Adult,
Older
Adult United States